Effect of EGFR/ERK inhibitors on the distribution of activated ERK (pERK) in mCMV-infected NB + 6 and NB + 12 SMGs. A-D. NB + 6 SMGs. E-H. NB + 12 SMGs. mCMV induces a notable increase in pERK expression in NB + 6 (B) and NB + 12 (F) SMGs compared to uninfected NB + 6 (A) and NB + 12 (E) controls (compare B to A and F to E). GEF-treated (C) and U0126-treated (D) mCMV-infected NB + 6 SMGs show a notable decrease in immunodetectable pERK compared to untreated mCMV-infected SMGs (compare C, D to B); the near absence of pERK with U0126 treatment resembles that seen in controls (compare D to A). By day 12, there is a marked increase in pERK expression in both GEF-treated (G) and U0126-treated (H) mCMV-infected SMGs compared to day 6 (compare G to C and H to D); pERK expression more closely resemblesuntreated, mCMV-infected SMGs seen on day 6 (compare G, H to B) than to controls (compare G, H to E). Bar: A-F, H- 50 μm, G- 60 μm.